When the K-cup patent expired Keurig tried to promote their "Vue" cups, some of which actually carried RFID chips that interacted with the brewer. Vue cups were bigger, didn't fit in the K-cup style brewer, and cost around twice as much as K-cups. You could get an adapter to use K-cups in a Vue brewer, which was great when those machines were cleared out super cheap because no one bought them.
Outside of making 3D printers accessible I'm not sure how libraries could feasibly offer workshops. People don't only work in plastic, and presently 3D printing is a novelty for your average person.
With the Chicago library's lab, they offer various workshops on some small example projects (e.g. a 3D printed trinket or a laser cut greeting card) to expose people to the basic process and offer open lab hours. You can look at the schedule here. I'm not sure where you see a problem with the feasibility of this.
3D printing is to a large extent still in the novelty phase, but as it gains in popularity so will the practical applications. I have a broken plastic component of a relay in a 70s era pinball machine for which purchasing a replacement isn't an option. It is however a simple geometric design and I plan on printing a replacement at the library.
The examples you site are all on broadcast networks available free over the air. I can have a data connection and still get free OTA channels. That's my plan as a late-twenty something. Netflix and hulu will do me just fine.
Article says they're dropping first-class Saturday delivery, no mention of priority or express. If you need something delivered ASAP, you probably aren't sending it first-class.
My current Asus router (dd-WRT) and the Buffalo router it replaced (tomato) have been flawless. I remember having a Linksys WRT54G with a legitimate hardware issue years ago and having to jump through a massive array of hoops to actually convince of it. There was a massive chain of emails every single question of which could have been answered by reading the first email I sent. No love lost here.
Is legacy access. When a given journal shuts down, the articles they did publish are still available from the publisher for perpetuity digitally or physical copies archived in the library. Free open journals are great, but we need a way to ensure anything published will be accessible even if their servers went down. My University cancelled their subscription to one journal I frequently read articles from, but I can still get PDFs of the physical copies that came with that subscription from the library archives. A huge part of science is being able to refer back to what has already been done.
$1,400 for a 4 credit class = $350/credit. In the SUNY system here in New York, part time enrollment once you factor in fee runs ~$280/credit in-state.
It would mean I'd need to own about half as many sockets and wrenches. Or eventually after a long enough time some future generation would. Also, not knowing if a random bolt is metric/imperial it's a pain to have to go back and forth to gauge the best fit.
With Win 7 upgrade they took the fresh install option away at one point, though I don't know if they've since restored it. Well, it would install fine but the upgrade license wouldn't activate unless you went in to the registry to changed the id to having been an upgrade install.
I get upgrade copies of windows from my University for like $8. I have a CD binder with Win XP (no sp, sp1, sp2, sp3, x64), Vista, Win7 (x32, x64). That includes multiple copies of some where I had friends pick them up.
Summary and TFA seem to skim over the main area where this technology will likely see application--in looking at drug permeability and transport across the intestinal membrane. This is something that gets examined for EVERY orally administered drug and right now this is done primarily with cell culture monolayers of intestinal cells. This model allows for the addition of peristaltic forces and other stressors to give a more physiologically relevant system.
You clearly misunderstood the post you're responding to, or are yourself, an
Idiot.
The poster implied that he would sell the rights to a pharma company and indeed licensing compounds from smaller companies/research labs is indeed standard practice. If you meant that the pharma companies don't have enough new drugs of their own, this is in fact wrong.
The second part of the post implied the kid would never be heard from again. If he made enough money it's possible. I'm guessing you misinterpreted this as a statement the company would buy his compound and it would never see the light of day, thus garnering your idiot comment. While it's not what he meant, it is in fact also common practice in pharma for companies to license the rights to compounds similar to those they are developing just to eliminate potential competition. It's why often when licensing a compound stipulations are added that the purchasing company must intend to develop it.
All of this is likely moot as the kid does not own the rights to the compounds. TFA doesn't specify whether they are novel but my guess would be he worked with a library of existing compounds that showed some activity against cystic fibrosis in preliminary screenings.
One of the problems with warfarin is that there is a lot of variability between patients. The main clearance enzyme for warfarin, CYP2C9, has reduced function in around roughly 25% of patients due to genetic polymorphisms. The target for warfarin, VKORC1, is highly variable due to genetics and the substrate concentrations, vitamin K, can vary greatly with dietary intake. Warfarin also has a narrow therapeutic window. If concentrations are too high there can be bleeding problems and at concentrations too low it's ineffective.
The end result is that the initial warfarin dosing can be extremely variable and requires close therapeutic monitoring when starting a new patient on the treatment. It's a far cry from something like aspirin where there is a pretty good idea of what dose a patient will need. A drug company producing something similar to warfarin that wasn't subject to such high genetic variability would be clinically preferred due to lower health care costs in starting treatment on new patients. That said, when you're properly dosed warfarin is pretty damn effective.
Slashdot Mirror
When the K-cup patent expired Keurig tried to promote their "Vue" cups, some of which actually carried RFID chips that interacted with the brewer. Vue cups were bigger, didn't fit in the K-cup style brewer, and cost around twice as much as K-cups. You could get an adapter to use K-cups in a Vue brewer, which was great when those machines were cleared out super cheap because no one bought them.
Outside of making 3D printers accessible I'm not sure how libraries could feasibly offer workshops. People don't only work in plastic, and presently 3D printing is a novelty for your average person.
With the Chicago library's lab, they offer various workshops on some small example projects (e.g. a 3D printed trinket or a laser cut greeting card) to expose people to the basic process and offer open lab hours. You can look at the schedule here. I'm not sure where you see a problem with the feasibility of this.
3D printing is to a large extent still in the novelty phase, but as it gains in popularity so will the practical applications. I have a broken plastic component of a relay in a 70s era pinball machine for which purchasing a replacement isn't an option. It is however a simple geometric design and I plan on printing a replacement at the library.
The examples you site are all on broadcast networks available free over the air. I can have a data connection and still get free OTA channels. That's my plan as a late-twenty something. Netflix and hulu will do me just fine.
Article says they're dropping first-class Saturday delivery, no mention of priority or express. If you need something delivered ASAP, you probably aren't sending it first-class.
He's a hardware architect that's been out of work since 3dfx closed down, you insensitive clod!
My current Asus router (dd-WRT) and the Buffalo router it replaced (tomato) have been flawless. I remember having a Linksys WRT54G with a legitimate hardware issue years ago and having to jump through a massive array of hoops to actually convince of it. There was a massive chain of emails every single question of which could have been answered by reading the first email I sent. No love lost here.
Is legacy access. When a given journal shuts down, the articles they did publish are still available from the publisher for perpetuity digitally or physical copies archived in the library. Free open journals are great, but we need a way to ensure anything published will be accessible even if their servers went down. My University cancelled their subscription to one journal I frequently read articles from, but I can still get PDFs of the physical copies that came with that subscription from the library archives. A huge part of science is being able to refer back to what has already been done.
$1,400 for a 4 credit class = $350 /credit. In the SUNY system here in New York, part time enrollment once you factor in fee runs ~$280 /credit in-state.
It would mean I'd need to own about half as many sockets and wrenches. Or eventually after a long enough time some future generation would. Also, not knowing if a random bolt is metric/imperial it's a pain to have to go back and forth to gauge the best fit.
2013, year of the Linux deskt..... wait, what?
When you can just use a sausage.
With Win 7 upgrade they took the fresh install option away at one point, though I don't know if they've since restored it. Well, it would install fine but the upgrade license wouldn't activate unless you went in to the registry to changed the id to having been an upgrade install.
I get upgrade copies of windows from my University for like $8. I have a CD binder with Win XP (no sp, sp1, sp2, sp3, x64), Vista, Win7 (x32, x64). That includes multiple copies of some where I had friends pick them up.
just in time for the semester to end and to take it all down. Sadly, that emergency party never did arrive.
Sublimation is, by definition, solid-->gas without forming a liquid intermediate.
Summary and TFA seem to skim over the main area where this technology will likely see application--in looking at drug permeability and transport across the intestinal membrane. This is something that gets examined for EVERY orally administered drug and right now this is done primarily with cell culture monolayers of intestinal cells. This model allows for the addition of peristaltic forces and other stressors to give a more physiologically relevant system.
Lightening even.
I don't know, with that tin foil hat maybe you should be more worried about lighting too.
I personally don't run with any anti virus on my home PCs. The trick is just not installing untrusted aps. So I'm sorry you have any antivirus at all.
Any takers on how many trojans/rootkits this guy is hoarding?
To scan 200,000 lottery tickets and sort out the winners.
There != their
Idiot.
The poster implied that he would sell the rights to a pharma company and indeed licensing compounds from smaller companies/research labs is indeed standard practice. If you meant that the pharma companies don't have enough new drugs of their own, this is in fact wrong.
The second part of the post implied the kid would never be heard from again. If he made enough money it's possible. I'm guessing you misinterpreted this as a statement the company would buy his compound and it would never see the light of day, thus garnering your idiot comment. While it's not what he meant, it is in fact also common practice in pharma for companies to license the rights to compounds similar to those they are developing just to eliminate potential competition. It's why often when licensing a compound stipulations are added that the purchasing company must intend to develop it.
All of this is likely moot as the kid does not own the rights to the compounds. TFA doesn't specify whether they are novel but my guess would be he worked with a library of existing compounds that showed some activity against cystic fibrosis in preliminary screenings.
Okay, we'll be Planet A and you can be Planet 1.
Come on google, enough bullshit. Leave the non-critical tweaks until after you've fixed the goddamn "print selection" option.
I'm not sure I quite get the analogy. Can you explain it again using cars this time?
One of the problems with warfarin is that there is a lot of variability between patients. The main clearance enzyme for warfarin, CYP2C9, has reduced function in around roughly 25% of patients due to genetic polymorphisms. The target for warfarin, VKORC1, is highly variable due to genetics and the substrate concentrations, vitamin K, can vary greatly with dietary intake. Warfarin also has a narrow therapeutic window. If concentrations are too high there can be bleeding problems and at concentrations too low it's ineffective.
The end result is that the initial warfarin dosing can be extremely variable and requires close therapeutic monitoring when starting a new patient on the treatment. It's a far cry from something like aspirin where there is a pretty good idea of what dose a patient will need. A drug company producing something similar to warfarin that wasn't subject to such high genetic variability would be clinically preferred due to lower health care costs in starting treatment on new patients. That said, when you're properly dosed warfarin is pretty damn effective.